InnoProTherapeutics Secures Angel+ Funding to Integrate Proteomics Platform with Drug Development

Investment Circle (ID: pedaily2012) July 24 News: Innovmab Therapeutics (Shanghai) Co., Ltd. ("Innovmab Therapeutics") has completedAngel+ Round Financing. To deeply integrate the proteomics technology platform with drug development and create multiple ADC pipelines with best-in-class potential.

Innovmab Therapeutics is a company driven by omics big data to develop targeted drugs and novel precision medical decision-making tools. Based on proteomics technology and various highly clinically relevant disease model libraries such as PDX/PDO, the company has established a unique drug R&D decision-making tool platform. By leveraging highly clinically relevant big data and deep biological insights obtained through AI computation, Innovmab advances the high success rate development of its proprietary new drug pipelines and IVD products. This technology platform provides rational decision-making data support for multiple key stages of new drug development, including target discovery, drug mechanism of action, patient selection, clinical trial design, determination of interim/surrogate endpoints in clinical studies, combination therapy development, clinical medication decision support, and drug indication expansion.

In terms of drug development, the company currently has multiple preclinical ADC new drug pipelines with innovative concepts, including products with unique targets based on more than a decade of academic research, which have the potential to become first-in-class products, giving the company a differentiated competitive advantage. Innovmab Therapeutics, supported by its organoid multi-omics platform, will achieve efficient and high-success-rate development of this ADC drug and simultaneously advance the development of combination therapies based on this product. Combination therapy is one of the most important developmental directions for ADC drugs. Through combination therapy, the effective dose of ADCs can be significantly reduced, side effects minimized, and the therapeutic window expanded.

This technology platform will also be applied to the development of precise diagnostic and therapeutic markers for diseases. Innovmab Therapeutics' organoid multi-omics platform uses AI algorithms to establish relationships between drug efficacy and multi-omics data, enabling the screening of more accurate combinations of drug efficacy markers and providing clinicians with a basis for precise medication decisions. Its core LDT product under development can simultaneously detect the activity of eight drug efficacy-related protein factors, offering guidance for targeted drugs based on the HER signaling pathway. It covers various indications, including breast cancer, non-small cell lung cancer, colorectal cancer, gastric cancer, pancreatic cancer, ovarian cancer, and melanoma. This product has the potential to evolve into a multi-target detection IVD kit for tumor pathology slides, introducing an entirely new concept.

Dr. Zheng Yong, founder and CEO of Innovmab Therapeutics, is an overseas high-level talent in Beijing and a specially appointed expert. His educational background includes a bachelor's degree from Lanzhou University, a master's degree from Peking Union Medical College, and a Ph.D. from the University of Alberta in Canada. He completed his postdoctoral training at the University of Toronto under the mentorship of the world-renowned Canadian cancerologist, Academician Tony Pawson. Dr. Zheng has served as an assistant researcher at the Lunenfeld-Tanenbaum Research Institute (LTRI) of Mount Sinai Hospital and as a professor and doctoral supervisor at the National Center for Protein Science (Beijing). He published a landmark article on proteomics in Nature and received support from multiple research funds, including the National Key R&D Program and the National Natural Science Foundation. Dr. Zheng Dexian, co-founder and chief scientist, is a professor at the School of Basic Medicine, Peking Union Medical College, and an expert receiving special allowances from the State Council. His education and professional experience include an undergraduate degree from Peking University, a joint Ph.D. program between the U.S. NIH and China CMMS, postdoctoral work at the U.S. FDA, and serving as a visiting professor at Harvard Medical School. He was previously the dean of the School of Basic Medicine at Peking Union Medical College, director and chair of the Academic Committee of the State Key Laboratory of Experimental Hematology, vice president of the Chinese Society of Immunology, and executive council member of the International Union of Immunological Societies. He led several major national projects such as "863," "973," and the National Major New Drug Innovation Program. Dr. Zheng also served as the chief scientist and R&D president of OBiO Technology, where he led the development of three new drug INDs and obtained 15 patents approved both domestically and internationally.The company boasts a multidisciplinary core team. Members have backgrounds from prestigious institutions such as Harvard University, the University of Toronto, the Wharton School, Tsinghua University, Peking University, Peking Union Medical College, the National Center for Protein Science, and the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences. They also bring executive experience from top pharmaceutical companies like Pfizer, Takeda, and Fosun Pharma, as well as leading technology firms such as Apple, Tencent Healthcare, and Alibaba Health.

Founder and CEO of Innovmab Therapeutics, Zheng YongRepresentation: Innovating healthcare and pharmaceutical R&D models through proteomics technology is an emerging international trend. Several cutting-edge companies overseas have garnered significant attention and support from investors, demonstrating development progress that exceeds expectations. Compared to our对标 enterprises, although we started slightly later, we possess unique technological advantages, including the latest generation of ADC pipeline technology, world-class proteomics expertise, and a distinctive organoid model library. I firmly believe that our new drug pipeline + clinical diagnostic tools + clinical omics big data + AI computing model represents the optimal path to achieving AI-driven drug discovery. Special thanks go to蒲公英医药创投 (Pugongying Healthcare Venture Capital) and Mr. Zhang for their trust and support! Mr. Zhang’s extensive resources and hands-on experience in the pharmaceutical industry, along with the efficient and pragmatic work ethic of the entire蒲公英 team, will provide crucial guidance and assistance for the business growth and commercialization of Innovmab Therapeutics.

Founder and Chairman of Dandelion, Zhang JinweiRepresentation: The complex network of proteins and their compositions are the ultimate executors of life activities, so protein-related information measured by proteomics is directly associated with disease states. The enormous potential of proteomics has started to gain recognition from capital, and Innovmab Therapeutics possesses world-class proteomics technology as well as a unique organoid model library. Its pipeline of new drugs + clinical testing tools + clinical omics big data + AI computing model represents an ideal path for realizing AI drug development and precision medicine.